CA19-9

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 2235678 Experts worldwide ranked by ideXlab platform

Liang Ming - One of the best experts on this subject based on the ideXlab platform.

  • Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer.
    Asian Pacific Journal of Cancer Prevention, 2014
    Co-Authors: Jing Bian, Bo Li, Xian-juan Kou, Xu'na Wang, Xiao-xu Sun, Liang Ming
    Abstract:

    Purpose: To assess the value of multi-tumor marker protein chips in the diagnosis and treatment of ovarian cancer. Materials and Methods: Twelve tumor markers (CA19-9, NSE, CEA, CA242, CK19, β-HCG, AFP, SCC, c-PSA, CA125, CA724 and CA15-3) were detected by protein biochip in 220 patients with ovarian carcinomas, 205 with benign ovarian tumors and 200 healthy subjects. Results: The positivity rate was obviously higher in ovarian cancer (77.7%), than that in the benign cases (26.3%, p

Masaki Kitajima - One of the best experts on this subject based on the ideXlab platform.

  • Prognostic values of serum CA19-9 and CEA levels for colorectal cancer.
    Oncology reports, 1997
    Co-Authors: T. Nakayama, Masahiko Watanabe, T Teramoto, Masaki Kitajima
    Abstract:

    CA19-9 and CEA are associated with gastrointestinal malignancy as adhesion molecules. We measured serum CA19-9 and CEA levels in 328 patients with colorectal cancer. Both serum CA19-9 and CEA levels correlated significantly with recurrence and survival, respectively. Serum CA19-9 levels correlated significantly with survival according to Astler-Coller stage and multivariate analysis. Serum CEA levels showed no such correlations, although the combination of CEA with CA19-9 improved the sensitivity for predicting recurrence. Assessment of serum CA19-9 levels is more important than that of CEA in the clinical management of patients with colorectal cancer.

  • CA19‐9 as a predictor of recurrence in patients with colorectal cancer
    Journal of surgical oncology, 1997
    Co-Authors: Takamori Nakayama, Masahiko Watanabe, Tatsuo Teramoto, Masaki Kitajima
    Abstract:

    Background and Objectives CA19-9 is a cancer-associated carbohydrate antigen that plays a role in the process of tumor progression as an adhesion molecule. Methods We evaluated the prognostic value of CA19-9 tumor expression and CA19-9 preoperative and postoperative serum levels in colorectal cancer patients treated by complete resection. The most powerful discrimination was achieved using the three CA19-9 markers in combination. Results CA19-9 tumor expression was identified by immunostaining in 71.0% (86/121) of primary carcinomas. Positive CA19-9 serum levels (≥37 U/ml) were restricted to cases with positive tumor expression, and CA19-9 was detected more frequently in preoperative serum (20.6%, 25/121) than in 1-month postoperative serum (6.6%, 8/121). Positive tumor expression, positive preoperative serum level, and positive postoperative serum level were all predictive of increased cancer mortality. Patients with three negative parameters had no recurrences and 97.1% 5-year survival, whereas patients with three positive parameters had 62.5% recurrence and 42.8% 5-year survival. Conclusions CA19-9 detection in tumor tissue and serum identified patients at high risk of cancer recurrence and death and may be useful in selecting patients for adjuvant therapy. J. Surg. Oncol. 1997;66:238–243. © 1997 Wiley-Liss, Inc.

Jing Bian - One of the best experts on this subject based on the ideXlab platform.

  • Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer.
    Asian Pacific Journal of Cancer Prevention, 2014
    Co-Authors: Jing Bian, Bo Li, Xian-juan Kou, Xu'na Wang, Xiao-xu Sun, Liang Ming
    Abstract:

    Purpose: To assess the value of multi-tumor marker protein chips in the diagnosis and treatment of ovarian cancer. Materials and Methods: Twelve tumor markers (CA19-9, NSE, CEA, CA242, CK19, β-HCG, AFP, SCC, c-PSA, CA125, CA724 and CA15-3) were detected by protein biochip in 220 patients with ovarian carcinomas, 205 with benign ovarian tumors and 200 healthy subjects. Results: The positivity rate was obviously higher in ovarian cancer (77.7%), than that in the benign cases (26.3%, p

Ji-zong Zhao - One of the best experts on this subject based on the ideXlab platform.

  • Clinical significance of CA19-9 in diagnosis of digestive tract tumors.
    World journal of gastroenterology, 1997
    Co-Authors: Ji-zong Zhao
    Abstract:

    AIM: To evaluate the clinical value of CA19-9 in diagnosing and differentiating gastrointestinal tumors and in monitoring patients treated surgically. METHODS: Patients with gastric cancer (n = 70), colorectal cancer (n = 90), pancreatic cancer (n = 7), esophageal cancer (n = 10) and benign disorders (n = 30), and normal adults (n = 111; used as healthy controls), were studied. Fasting blood samples were obtained from each study participant. The serum CA19-9 concentration was measured with radioimmunoassay. RESULTS: The mean CA19-9 level was significantly higher in patients with gastric cancer (170.69 ± 91.45 kU/L) and patients with colorectal cancer (87.21 ± 39.55 kU/L) than in the healthy controls (11.254 ± 6.00 kU/L). Compared with the healthy controls, the CA19-9 level was also much higher in patients with pancreatic cancer (1266.58 ± 521.31 kU/L) (P 0.05). The demarcation value of CA19-9 between negative and positive was < 31.0 kU/L. The sensitivity of CA19-9 for gastric, colorectal, pancreatic and esophageal cancers and for gastrointestinal benign disorders was 47.3%, 50.0%, 83.3%, 20.0% and 0%, respectively. The specificity of CA19-9 for digestive system malignant diseases was 100% for all.

Guang-shun Yang - One of the best experts on this subject based on the ideXlab platform.

  • Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma
    International Journal of Clinical and Experimental Pathology, 2014
    Co-Authors: Gong-hao He, Jun-hua Lu, Hua Wang, Guang-shun Yang
    Abstract:

    To investigate the appropriate cutoff point of CA19-9 for prognosis and other potential prognostic factors that may affect survival of patients with hilar cholangiocarcinoma (HC) after radical surgery. 168 patients who had undergone radical surgery for hilar cholangiocarcinoma and resultant macroscopic curative resection (R0 and R1) were discreetly selected for analyses. Categorized versions were used in univariate model to determine the appropriate cutoff point of CA19-9. CA19-9 and other clinicopathologic factors were analyzed for influence on survival by univariate and multivariate methods. The strongest univariate predictor among the categorized preoperative CA19-9 measures was CA19-9 less than 150 IU/L (P = 0.000). In univariate analysis, tumor size, Bismuth-Corlette classification, portal vein invasion, Lymph node metastasis, resection margin and preoperative CA19-9 levels were identified as significant prognostic factors. In multivariable analysis, lymph node metastasis, resection margin and preoperative CA19-9 levels were independent prognostic factors. our results demonstrated that preoperative CA19-9 levels was also an independent prognostic factor for hilar cholangiocarcinoma, and the most discriminative cutoff point of CA19-9 for prognosis proved to be at 150 U/ml.